Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Genetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma
Authors:ID Šetina, Matic (Author)
ID Šetina, Eva (Author)
ID Doljak, Žiga (Author)
ID Goričar, Katja (Author)
ID Dolžan, Vita (Author)
ID Kovač, Viljem (Author)
Files:.pdf PDF - Presentation file, download (499,50 KB)
MD5: DD7D52949E8B7B1B968CE231D7A9DA17
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. Treatment of malignant mesothelioma (MM) still relies on chemotherapy with cisplatin in combination with pemetrexed or other drugs. Studies indicate that hypoxic conditions within tumour tissue may reduce responsiveness to cisplatin-based chemotherapy. Hypoxia-inducible factors (HIF) play an important role in regulation of cellular adaptation to hypoxia. The aim of our study was to investigate single nucleotide polymorphisms (SNPs) in the HIF1A gene coding for the regulatory alpha subunit (HIF-1A) and their role in the response to chemotherapy in patients with MM. Patients and methods. Our retrospective genetic association study included 234 patients with MM, who were treated with a combination of cisplatin/pemetrexed or cisplatin/gemcitabine at the Institute of Oncology Ljubljana between January 2001 and September 2018. Selected HIF1A SNPs (rs1154965, rs11549467, and rs2057482) were genotyped using the competitive allele-specific polymerase chain reaction (KASP). Additionally, we used a TaqMan assay for independent confirmation of rs11549465 genotyping results. The impact of the SNPs on response to chemotherapy was analysed using logistic regression. For survival analysis, we used the Kaplan-Meier method and Cox regression. Results. In heterozygotes with the HIF1A rs11549465 CT genotype, response to chemotherapy was significantly worse compared to homozygotes with the CC genotype, but only after adjustment for weight loss and CRP (ROadj = 0.37; 95% CI = 0.14–0.97; Padj = 0.044). HIF1A rs11549467 and rs2057482 were not associated with response to chemotherapy (all P > 0.05). None of the investigated SNPs were associated with progression-free survival or overall survival (all P > 0.05). Conclusions. Among the investigated HIF1A SNPs, only rs11549465 has showed association with a worse response to chemotherapy after the adjustment for clinical parameters. The findings of this study have improved our understanding of the role of HIF1A polymorphisms in MM and may offer valuable insights into their impact on other cancers as well.
Keywords:malignant mesothelioma, chemotherapy, polymorphism
Publication status:Published
Publication version:Version of Record
Submitted for review:15.06.2025
Article acceptance date:19.07.2025
Publication date:01.09.2025
Place of publishing:Ljubljana
Publisher:Association of Radiology and Oncology
Year of publishing:2025
Number of pages:str. 403-411
Numbering:Vol. 59, no. 3
Source:Ljubljana
PID:20.500.12556/DiRROS-24569 New window
UDC:616.2
ISSN on article:1318-2099
DOI:10.2478/raon-2025-0049 New window
COBISS.SI-ID:246330371 New window
Copyright:by Authors
Publication date in DiRROS:10.12.2025
Views:63
Downloads:15
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L3-2622-2020
Name:Biološki označevalci nastanka, napredovanja in odgovora na zdravljenje bolezni povezanih z izpostavljenostjo azbestu

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L1-60135-2025
Name:Cirkulirajoči zunajcelični vezikli kot vir multi-omskih označevalcev nastanka bolezni povezanih z izpostavljenostjo azbestu in odgovora na zdravljenje pri malignem mezoteliomu

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0170-2018
Name:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:maligni mezoteliom, kemoterapija, polimorfizem


Back